New imaging agent could light up Hard-to-See cancers
NCT ID NCT07117214
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The agent is designed to bind to a target on cancer cells and show up on PET scans, helping doctors see where the cancer has spread. The main goals are to check how well the imaging works, how the agent spreads in the body, and whether it is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[68Ga]Ga-DWJ155 (a radioactive imaging agent for PET scans)
What this could lead to
If successful, this could lead to a better way to detect and monitor advanced breast cancer and lung cancer using PET imaging, potentially guiding treatment decisions.
What could go wrong
This is a very early, first-in-human study with only 36 participants. The imaging agent may not clearly distinguish tumors from normal tissue, or safety issues could arise. It is not a treatment and will not directly improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGGroningen, 9728, Netherlands